viewHumanigen, Inc.

Humanigen wins hematological society award for leukemia treatment presentation

The company won an Abstract Achievement Award for one of its two presentations at the American Society of Hematology's annual meeting

The drug, a monoclonal antibody, works to improve CAR-T, a new approach to cancer therapy involving altered T cells

Humanigen Inc (OTCMKTS:HGEN) received an award from the American Society of Hematology (ASH) after presenting an abstract at the organization's annual meeting last week.

The company won a 2019 ASH Abstract Achievement Award for one of its two presentations, which showed results from a study of its drug candidate lenzilumab.

The drug, a monoclonal antibody, works to improve CAR-T, a new approach to cancer therapy involving altered T cells. Humanigen said a xenograft model for relapsed acute lymphoblastic leukemia showed improved overall survival compared to another treatment called CART19.

READ: Humanigen to present abstracts highlighting its glioblastoma treatments at industry conference

Specifically, it works to neutralize the protein GM-CSF using activated CAR-T cells, a modified form of the white blood cell subset.

"It is gratifying to receive recognition for the second year in succession that we have presented GM-CSF -related data for the pioneering work that we are conducting to make CAR-T therapy potentially more efficacious and safer through GM-CSF neutralization," CEO Cameron Durrant said in a statement. "We are looking forward to bringing lenzilumab into the clinic as we begin dosing patients in ZUMA-19 in 2020 with our partner, Kite Pharma."

The Burlingame, California-based company plans to work with Kite to study lenzilumab as a potential treatment for patients with relapsed diffuse large B-cell lymphoma. 

Kite, owned by Gilead Sciences Inc (NASDAQ:GILD), has developed the drug Yescarta, which lenzilumab will be paired with, in the study.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: - -

Market: OTCQB
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...


Integumen PLC to seek fast-track approval for its new coronavirus breath test

Integumen PLC's (LON:SKIN) Gerry Brandon speaks to Proactive's Andrew Scott after unveiling a new personalised coronavirus breath test, Microtox BT, and a complimentary digital health pass platform which he says has the potential to enable instant real-time testing for the virus. Brandon says...

1 hour, 37 minutes ago

2 min read